Paul Tudor Jones Kura Oncology, Inc. Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$9.62 - $13.99 $335,151 - $487,397	34,839 New	34,839 $368,000
Q1 2022 May 16, 2022	SELL	$11.78 - $16.98 $434,010 - $625,594	-36,843 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $450,221 - $721,017	36,843 New	36,843 $516,000
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $304,821 - $482,048	-12,316 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $357,164 - $512,591	12,316 New	12,316 $402,000
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $264,039 - $373,593	-17,901 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $263,323 - $354,260	17,901 New	17,901 $352,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.